Welcome to our dedicated page for OCEL news (Ticker: OCEL), a resource for investors and traders seeking the latest updates and insights on OCEL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OCEL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OCEL's position in the market.
Organicell Regenerative Medicine (OTCQB:OCEL) has secured an additional $1 million in private stock purchases at $0.04 per share and a $10 million Equity Line of Credit with Tysadco Partners, bringing total funding to $16.5 million. The FDA has approved Phase I/II trials for its investigational drug Zofin™, aimed at treating Covid Long Hauler and COPD. CEO Matt Sinnreich emphasized the need for swift patient enrollment and secured funds to support ongoing trials.
Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) closed a $5.5 million funding round, consisting of a $4.0 million capital raise at $0.02 per share and an additional $1.5 million at $0.04 per share. This capital will enhance technology operations, advance clinical trials, and support business integration. Bob Smoley, a telehealth pioneer, will advise the Company. Organicell emphasizes a fresh start, focusing on second chances and leveraging Smoley's network. They specialize in innovative biological therapeutics for degenerative diseases.
Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) has appointed Matt Sinnreich as Chief Operating Officer and acting CEO, replacing founder Albert Mitrani, who moves to EVP of sales. Sinnreich, an early-stage investor, has previous experience in financing and real estate. His priorities include enhancing financing vehicles, raising brand awareness, and building a core executive team. He will also launch Patient Pure X™ (PPX™), focusing on clinical studies related to pain, hair loss, and aesthetic applications. The company aims to disrupt the biotech industry with its innovative exosome-based products.
Organicell Regenerative Medicine (OTCQB:OCEL) announced securing $4.0 million in funding for clinical trials and working capital. The investment comes from two groups led by MDLive's founders and Dr. B.K. Modi. Each group will purchase 100 million shares at $2.0 million total. Part of the proceeds will start FDA-approved Phase I/II trials for Zofin™, targeting COVID-19 long haulers, COPD, and osteoarthritis. As part of the deal, corporate governance changes include new independent directors and management restructuring, with CEO Albert Mitrani stepping down.
Organicell Regenerative Medicine (OTCQB:OCEL) has initiated its first clinical site for a Phase I/II randomized trial to test Zofin™ on patients with prolonged COVID-19 symptoms, known as Long Haulers. The trial, led by Dr. Ryan Klein at NewportNativeMD, aims to enroll 30 patients over 12 months and is expected to complete by August 2023. Zofin™, an acellular therapeutic, contains over 300 growth factors and microRNAs. Successful results could lead to a Phase II/III trial and FDA approval amendment. The prevalence of Long COVID affects over 100 million globally, heightening the trial's significance.
Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) reported updates on its investigational drug applications and clinical trials for Zofin™, an acellular biologic therapy. The FDA has granted IND and emergency eIND approvals, allowing physicians to treat patients with Zofin™ when no other therapies are available. Results from 11 eIND patients showed varied outcomes, some improving significantly, while others faced critical conditions and mortality. The company is awaiting FDA approval for its randomized controlled trials, and there have been no reported severe adverse events associated with Zofin™.
Organicell Regenerative Medicine (OCEL) has received approval to uplist its common stock to the OTCQB Venture Market, effective November 9, 2021. This uplisting signifies compliance with financial reporting standards and enhances the company's visibility, potentially increasing access to institutional and retail investors. Organicell aims to leverage this new platform for capital raising in support of clinical trials for its lead product, Zofin™, a biologic therapy derived from perinatal sources.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) has announced that FINRA has approved its marketplace name change to Organicell Regenerative Medicine, Inc. and trading symbol change to OCEL. This change will take effect on November 8, 2021, with no action required from stockholders. The name change aims to reduce confusion in the market.
Organicell specializes in developing regenerative therapies using exosomes for treating degenerative diseases, focusing on innovation in biopharmaceuticals.